ClinicalTrials.gg
CompletedNCT05421078Updated Oct 29, 2024Results posted

A Dose-Finding Study in Japanese Patients to Evaluate the Effect of Obicetrapib as an Adjunct to Stable Statin Therapy.

A Phase 2 interventional study of Obicetrapib and Placebo in Dyslipidemia, Hypercholesterolemia and High Cholesterol, sponsored by NewAmsterdam Pharma. Completed at 10 sites in Japan. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-10-29.

Primary conditionHypercholesterolemiaRegistry: DyslipidemiasReclassifiedWhy we changed it
Registry
Dyslipidemias — the first condition term the registry derived for this study.
ClinicalTrials.gg
Hypercholesterolemia
Why
  1. The study's listed conditions name Hypercholesterolemia, a narrower term within Dyslipidemias.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by NewAmsterdam Pharma · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
102
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 53 studies in Hypercholesterolemia with a site in Japan — 2 open to participants now, 5 under way, 3 of them phase 3. Hypercholesterolemia · Japan.

Enrollment
41st of 50
102 · median 259
Started
2022
with 2 others
Phase 2
10 of 53
none open now
Registered
47th of 53
by date
Lead sponsor
2 of 53
NewAmsterdam Pharma

Among the 53 studies in Hypercholesterolemia with a site in Japan, this one is the 41st largest by enrollment of the 50 interventional ones that give a count, is one of 3 that started in 2022, is one of 10 in phase 2, and was the 47th registered.

Hypercholesterolemia

1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.

Browse Hypercholesterolemia studies →

Open to participants now

2 of the 53 studies in Hypercholesterolemia with a site in Japan are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in Japan have not opened yet or have stopped. Only those recruiting at a site in Japan →

Who these studies take

Of the 57 Hypercholesterolemia studies recruiting now, 25 (44%) set no upper age limit and 20 (35%) stop at 75 or younger; 10 take children under 18; 11 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 53 studies in Hypercholesterolemia with a site in Japan, or all of them as a file.
02

Study summary

This study will be a placebo-controlled, double-blind, randomized, phase 2 dose-finding study in Japanese patients to evaluate the efficacy, safety, and tolerability of obicetrapib as an adjunct to stable statin therapy.

Read the detailed description

This study will be a placebo-controlled, double-blind, randomized, phase 2 dose-finding study to evaluate the efficacy, safety, and tolerability of obicetrapib as an adjunct to stable statin therapy in Japanese patients. The screening period for this study will take up to 2-weeks. Afterwards, patients will be randomized to placebo, 2.5 mg obicetrapib, 5 mg obicetrapib or 10 mg obicetrapib for an 8-week treatment period. After the treatment period, patients will continue for a 4-week safety follow-up visit.

03

Conditions studied

  • Dyslipidemia
  • Hypercholesterolemia
  • High Cholesterol

Browse trials for

Keywords

  • obicetrapib
  • statin
  • LDL-C cholestero
  • l atherosclerosis
04

In context

Hypercholesterolemia Reclassified

1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.

This study's enrollment of 102 is close to the median of 110 across 976 interventional studies indexed under Hypercholesterolemia.

Browse Hypercholesterolemia studies →

Lead sponsor

NewAmsterdam Pharma is the lead sponsor of 20 studies on the registry; 3 are open to participants now.

Of its 13 completed or terminated interventional studies of FDA-regulated products, 8 (62%) have results posted.

Compared within Hypercholesterolemia, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Dyslipidemias. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • LDL-C > 70 mg/dL and TG \< 400 mg/dL,
  • Treated with a stable statin therapy; Atorvastatin 20/40 or Simvastatin 10/20

Exclusion criteria

Exclusion Criteria:

  • > or =35 kg/m2
  • Significant cardiovascular disease
  • > 10%
  • Uncontrolled hypertension
  • Active muscle disease
  • \< 60 ml/min
  • Hepatic dysfunction
  • Anemia
  • Existing CETP deficiency
  • History of Homozygous Familial Hypercholerstrolemia
  • History of
  • Alcohol abuse
  • Treatment with product
  • Treatment with PCSK9
  • condition
  • Known CETP inhibitor allergy
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

06

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
102 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Once-daily placebo

    Drug: Placebo

  • Experimental
    2.5 mg Obicetrapib

    once-daily Obicetrapib

    Drug: Obicetrapib

  • Experimental
    5 mg Obicetrapib

    once-daily Obicetrapib

    Drug: Obicetrapib

  • Experimental
    10 mg Obicetrapib

    once-daily Obicetrapib

    Drug: Obicetrapib

Interventions

  • tablet

    Also known as: CETP inhibitor

  • DrugPlacebo

    No active ingredient

    Also known as: placebo tablet

07

What researchers measure

Primary outcomes

  1. Mean Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) [Friedewald]

    Mean percent change from Day 1 to Day 56 in Low-Density Lipoprotein Cholesterol (LDL-C) for each obicetrapib group compared to the placebo group. LDL-C was calculated using the Friedewald equation unless TG≥400 mg/dL or LDL-C ≤50 mg/dL; if TG ≥400 mg/dL or LDL-C ≤50 mg/dL, then LDL-C level was measured directly by preparative ultracentrifugation (PUC).

    Time frame: 8 Weeks

  2. Median Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) [Friedewald]

    Median percent change from Day 1 to Day 56 in Low-Density Lipoprotein Cholesterol (LDL-C) for each obicetrapib group compared to the placebo group. LDL-C was calculated using the Friedewald equation unless TG≥400 mg/dL or LDL-C ≤50 mg/dL; if TG ≥400 mg/dL or LDL-C ≤50 mg/dL, then LDL-C level was measured directly by preparative ultracentrifugation (PUC).

    Time frame: 8 Weeks

  3. LS Mean Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) [Friedewald]

    LS Mean percent change from Day 1 to Day 56 in Low-Density Lipoprotein Cholesterol (LDL-C) for each obicetrapib group compared to the placebo group. LDL-C was calculated using the Friedewald equation unless TG≥400 mg/dL or LDL-C ≤50 mg/dL; if TG ≥400 mg/dL or LDL-C ≤50 mg/dL, then LDL-C level was measured directly by preparative ultracentrifugation (PUC).

    Time frame: 8 Weeks

  4. Mean Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) [PUC]

    Mean Percent change from Day 1 to Day 56 in Low-Density Lipoprotein Cholesterol (LDL-C) for each obicetrapib group compared to the placebo group. LDL-C level was measured by preparative ultracentrifugation (PUC).

    Time frame: 8 Weeks

  5. Median Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) [PUC]

    Median Percent change from Day 1 to Day 56 in Low-Density Lipoprotein Cholesterol (LDL-C) for each obicetrapib group compared to the placebo group. LDL-C level was measured by preparative ultracentrifugation (PUC)

    Time frame: 8 Weeks

  6. LS Mean Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) [PUC]

    Mean Percent change from Day 1 to Day 56 in Low-Density Lipoprotein Cholesterol (LDL-C) for each obicetrapib group compared to the placebo group. LDL-C level was measured by preparative ultracentrifugation (PUC).

    Time frame: 8 Weeks

Secondary outcomes

  1. Mean Percent Change in Apolipoprotein B (ApoB)

    Mean percent change from baseline to Day 56 in apolipoprotein B (ApoB) (mg/dL) for each obicetrapib group compared with the placebo group.

    Time frame: 8 Weeks

  2. Median Percent Change in Apolipoprotein B (ApoB)

    Median percent change from baseline to Day 56 in apolipoprotein B (ApoB) (mg/dL) for each obicetrapib group compared with the placebo group.

    Time frame: 8 Weeks

  3. LS Mean Percent Change in Apolipoprotein B (ApoB)

    Median percent change from baseline to Day 56 in apolipoprotein B (ApoB) (mg/dL) for each obicetrapib group compared with the placebo group.

    Time frame: 8 Weeks

  4. Mean Percent Change in Non-high-density Lipoprotein Cholesterol (Non-HDL-C)

    Mean percent change from baseline to Day 56 in non-high-density lipoprotein cholesterol (non-HDL-C) (mg/dL) for each obicetrapib group compared with the placebo group

    Time frame: 8 weeks

  5. Median Percent Change in Non-high-density Lipoprotein Cholesterol (Non-HDL-C)

    Median percent change from baseline to Day 56 in non-high-density lipoprotein cholesterol (non-HDL-C) (mg/dL) for each obicetrapib group compared with the placebo group

    Time frame: 8 Weeks

  6. LS Mean Percent Change in Non-high-density Lipoprotein Cholesterol (Non-HDL-C)

    LS Mean percent change from baseline to Day 56 in non-high-density lipoprotein cholesterol (non-HDL-C) (mg/dL) for each obicetrapib group compared with the placebo group

    Time frame: 8 Weeks

  7. Mean Percent Change in High-density Lipoprotein Cholesterol (HDL-C)

    Mean percent change from baseline to Day 56 in High-density lipoprotein cholesterol (HDL-C) (mg/dL) for each obicetrapib group compared with the placebo group

    Time frame: 8 weeks

  8. Median Percent Change in High-density Lipoprotein Cholesterol (HDL-C)

    Median percent change from baseline to Day 56 in High-density lipoprotein cholesterol (HDL-C) (mg/dL) for each obicetrapib group compared with the placebo group

    Time frame: 8 Weeks

  9. LS Mean Percent Change in High-density Lipoprotein Cholesterol (HDL-C)

    LS Mean percent change from baseline to Day 56 in High-density lipoprotein cholesterol (HDL-C) (mg/dL) for each obicetrapib group compared with the placebo group.

    Time frame: 8 Weeks

08

Results

Posted Sep 27, 2024

Participant flow

Participant flow — Overall Study
MilestonePlaceboExperimental 2.5 mg ObicetrapibExperimental 5 mg ObicetrapibExperimental 10 mg Obicetrapib
Started26252526
Completed26252526
Not completed0000

Outcome measures

PrimaryMean Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) [Friedewald]

Mean percent change from Day 1 to Day 56 in Low-Density Lipoprotein Cholesterol (LDL-C) for each obicetrapib group compared to the placebo group. LDL-C was calculated using the Friedewald equation unless TG≥400 mg/dL or LDL-C ≤50 mg/dL; if TG ≥400 mg/dL or LDL-C ≤50 mg/dL, then LDL-C level was measured directly by preparative ultracentrifugation (PUC).

Time frame:
8 Weeks
Reported as:
Mean · percent change from baseline
Mean Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) [Friedewald]
percent change from baselinePlacebo2.5 mg Obicetrapib5 mg Obicetrapib10 mg Obicetrapib
Mean Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) [Friedewald]-0.78 ± 14.581-25.90 ± 21.259-33.78 ± 13.247-36.80 ± 25.727
Statistical analysis
  • Placebo vs 2.5 mg Obicetrapib · Mixed Models Analysis · p = <.0001 (p value is calculated) · Least squares (ls) means: -25.84 · 95% CI -36.53 to -15.14mixed model for repeated measures (MMRM) with missing at random assumption
  • Placebo vs 5 mg Obicetrapib · Mixed Models Analysis · p = <.0001 (p value is calculated) · Least squares (ls) means: -33.34 · 95% CI -44.01 to -22.66mixed model for repeated measures (MMRM) with missing at random assumption
  • Placebo vs 10 mg Obicetrapib · Mixed Models Analysis · p = <.0001 (p value is calculated) · Least squares (ls) means: -36.12 · 95% CI -46.68 to -25.55mixed model for repeated measures (MMRM) with missing at random assumption
PrimaryMedian Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) [Friedewald]

Median percent change from Day 1 to Day 56 in Low-Density Lipoprotein Cholesterol (LDL-C) for each obicetrapib group compared to the placebo group. LDL-C was calculated using the Friedewald equation unless TG≥400 mg/dL or LDL-C ≤50 mg/dL; if TG ≥400 mg/dL or LDL-C ≤50 mg/dL, then LDL-C level was measured directly by preparative ultracentrifugation (PUC).

Time frame:
8 Weeks
Reported as:
Median · percent change from baseline
Median Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) [Friedewald]
percent change from baselinePlacebo2.5 mg Obicetrapib5 mg Obicetrapib10 mg Obicetrapib
Median Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) [Friedewald]-0.89 (-38.6 to 27.8)-24.81 (-66.0 to 17.7)-31.94 (-56.8 to -2.9)-45.80 (-73.0 to 45.5)
Statistical analysis
  • Placebo vs 2.5 mg Obicetrapib · Mixed Models Analysis · p = <.0001 · Least squares (ls) means: -25.84 · 95% CI -36.53 to -15.14mixed model for repeated measures (MMRM) with missing at random assumption
  • Placebo vs 5 mg Obicetrapib · Mixed Models Analysis · p = <.0001 (p value is calculated) · Least squares (ls) means: -33.34 · 95% CI -44.01 to -22.66mixed model for repeated measures (MMRM) with missing at random assumption
  • Placebo vs 10 mg Obicetrapib · Mixed Models Analysis · p = <.0001 (p value is calculated) · Least squares (ls) means: -36.12 · 95% CI -46.68 to -25.55mixed model for repeated measures (MMRM) with missing at random assumption
PrimaryLS Mean Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) [Friedewald]

LS Mean percent change from Day 1 to Day 56 in Low-Density Lipoprotein Cholesterol (LDL-C) for each obicetrapib group compared to the placebo group. LDL-C was calculated using the Friedewald equation unless TG≥400 mg/dL or LDL-C ≤50 mg/dL; if TG ≥400 mg/dL or LDL-C ≤50 mg/dL, then LDL-C level was measured directly by preparative ultracentrifugation (PUC).

Time frame:
8 Weeks
Reported as:
Least squares mean · percent change from baseline
LS Mean Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) [Friedewald]
percent change from baselinePlacebo2.5 mg Obicetrapib5 mg Obicetrapib10 mg Obicetrapib
LS Mean Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) [Friedewald]-0.48 ± 3.766-26.32 ± 3.844-33.82 ± 3.838-36.60 ± 3.765
Statistical analysis
  • Placebo vs 2.5 mg Obicetrapib · Mixed Models Analysis · p = <.0001 (p value is calculated) · Least squares (ls) means: -25.84 · 95% CI -36.53 to -15.14mixed model for repeated measures (MMRM) with missing at random assumption
  • Placebo vs 5 mg Obicetrapib · Mixed Models Analysis · p = <.0001 (p value is calculated) · Least squares (ls) means: -33.34 · 95% CI -44.01 to -22.66mixed model for repeated measures (MMRM) with missing at random assumption
  • Placebo vs 10 mg Obicetrapib · Mixed Models Analysis · p = <.0001 (p value is calculated) · Least squares (ls) means: -36.12 · 95% CI -46.68 to -25.55mixed model for repeated measures (MMRM) with missing at random assumption
PrimaryMean Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) [PUC]

Mean Percent change from Day 1 to Day 56 in Low-Density Lipoprotein Cholesterol (LDL-C) for each obicetrapib group compared to the placebo group. LDL-C level was measured by preparative ultracentrifugation (PUC).

Time frame:
8 Weeks
Reported as:
Mean · percent change from baseline
Mean Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) [PUC]
percent change from baselinePlacebo2.5 mg Obicetrapib5 mg Obicetrapib10 mg Obicetrapib
Mean Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) [PUC]0.43 ± 15.456-26.10 ± 23.477-30.50 ± 14.959-36.29 ± 24.513
Statistical analysis
  • Placebo vs 2.5 mg Obicetrapib · ANCOVA · p = <.0001 (p value is calculated) · Least squares (ls) means: -27.20 · 95% CI -38.37 to -16.04
  • Placebo vs 5 mg Obicetrapib · ANCOVA · p = <.0001 (p value is calculated) · Least squares (ls) means: -31.23 · 95% CI -42.36 to -20.10
  • Placebo vs 10 mg Obicetrapib · ANCOVA · p = <.0001 (p value is calculated) · Least squares (ls) means: -36.81 · 95% CI -47.83 to -25.80
PrimaryMedian Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) [PUC]

Median Percent change from Day 1 to Day 56 in Low-Density Lipoprotein Cholesterol (LDL-C) for each obicetrapib group compared to the placebo group. LDL-C level was measured by preparative ultracentrifugation (PUC)

Time frame:
8 Weeks
Reported as:
Median · percent change from baseline
Median Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) [PUC]
percent change from baselinePlacebo2.5 mg Obicetrapib5 mg Obicetrapib10 mg Obicetrapib
Median Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) [PUC]0.67 (-35.3 to 32.5)-25.97 (-67.6 to 41.9)-30.40 (-57.8 to -2.7)-43.72 (-72.0 to 30.9)
Statistical analysis
  • Placebo vs 2.5 mg Obicetrapib · ANCOVA · p = <.0001 (p value is calculated) · Least squares (ls) means: -27.20 · 95% CI -38.37 to -16.04
  • Placebo vs 5 mg Obicetrapib · ANCOVA · p = <.0001 (p value is calculated) · Least squares (ls) means: -31.23 · 95% CI -42.36 to -20.10
  • Placebo vs 10 mg Obicetrapib · ANCOVA · p = <.0001 (p value is calculated) · Least squares (ls) means: -36.81 · 95% CI -47.83 to -25.80
PrimaryLS Mean Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) [PUC]

Mean Percent change from Day 1 to Day 56 in Low-Density Lipoprotein Cholesterol (LDL-C) for each obicetrapib group compared to the placebo group. LDL-C level was measured by preparative ultracentrifugation (PUC).

Time frame:
8 Weeks
Reported as:
Least squares mean · percent change from baseline
LS Mean Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) [PUC]
percent change from baselinePlacebo2.5 mg Obicetrapib5 mg Obicetrapib10 mg Obicetrapib
LS Mean Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) [PUC]0.69 ± 3.928-26.51 ± 4.013-30.54 ± 4.002-36.12 ± 3.926
Statistical analysis
  • Placebo vs 2.5 mg Obicetrapib · ANCOVA · p = <.0001 (p value is calculated) · Least squares (ls) means: -27.20 · 95% CI -38.37 to -16.04
  • Placebo vs 5 mg Obicetrapib · ANCOVA · p = <.0001 (p value is calculated) · Least squares (ls) means: -31.23 · 95% CI -42.36 to -20.10
  • Placebo vs 10 mg Obicetrapib · ANCOVA · p = <.0001 (p value is calculated) · Least squares (ls) means: -36.81 · 95% CI -47.83 to -25.80
SecondaryMean Percent Change in Apolipoprotein B (ApoB)

Mean percent change from baseline to Day 56 in apolipoprotein B (ApoB) (mg/dL) for each obicetrapib group compared with the placebo group.

Time frame:
8 Weeks
Reported as:
Mean · percent change from baseline
Mean Percent Change in Apolipoprotein B (ApoB)
percent change from baselinePlacebo2.5 mg Obicetrapib5 mg Obicetrapib10 mg Obicetrapib
Mean Percent Change in Apolipoprotein B (ApoB)-1.23 ± 10.614-19.80 ± 15.363-24.48 ± 13.909-26.66 ± 15.0
Statistical analysis
  • Placebo vs 2.5 mg Obicetrapib · Mixed Models Analysis · p = <.0001 (p value is calculated) · Least squares (ls) means: -19.00 · 95% CI -25.83 to -12.18mixed model for repeated measures (MMRM) with missing at random assumption
  • Placebo vs 5 mg Obicetrapib · Mixed Models Analysis · p = <.0001 (p value is calculated) · Least squares (ls) means: -22.45 · 95% CI -29.28 to -15.62mixed model for repeated measures (MMRM) with missing at random assumption
  • Placebo vs 10 mg Obicetrapib · Mixed Models Analysis · p = <.0001 (p value is calculated) · Least squares (ls) means: -24.86 · 95% CI -31.62 to -18.10mixed model for repeated measures (MMRM) with missing at random assumption
SecondaryMedian Percent Change in Apolipoprotein B (ApoB)

Median percent change from baseline to Day 56 in apolipoprotein B (ApoB) (mg/dL) for each obicetrapib group compared with the placebo group.

Time frame:
8 Weeks
Reported as:
Median · percent change from baseline
Median Percent Change in Apolipoprotein B (ApoB)
percent change from baselinePlacebo2.5 mg Obicetrapib5 mg Obicetrapib10 mg Obicetrapib
Median Percent Change in Apolipoprotein B (ApoB)-0.36 (-26.1 to 21.7)-22.50 (-45.6 to 12.7)-21.43 (-53.4 to 1.0)-29.67 (-56.4 to 9.5)
Statistical analysis
  • Placebo vs 2.5 mg Obicetrapib · Mixed Models Analysis · p = <.0001 (p value is calculated) · Least squares (ls) means: -19.00 · 95% CI -25.83 to -12.18mixed model for repeated measures (MMRM) with missing at random assumption
  • Placebo vs 5 mg Obicetrapib · Mixed Models Analysis · p = <.0001 (p value is calculated) · Least squares (ls) means: -22.45 · 95% CI -29.28 to -15.62mixed model for repeated measures (MMRM) with missing at random assumption
  • Placebo vs 10 mg Obicetrapib · Mixed Models Analysis · p = <.0001 (p value is calculated) · Least squares (ls) means: -24.86 · 95% CI -31.62 to -18.10mixed model for repeated measures (MMRM) with missing at random assumption
SecondaryLS Mean Percent Change in Apolipoprotein B (ApoB)

Median percent change from baseline to Day 56 in apolipoprotein B (ApoB) (mg/dL) for each obicetrapib group compared with the placebo group.

Time frame:
8 Weeks
Reported as:
Least squares mean · percent change from baseline
LS Mean Percent Change in Apolipoprotein B (ApoB)
percent change from baselinePlacebo2.5 mg Obicetrapib5 mg Obicetrapib10 mg Obicetrapib
LS Mean Percent Change in Apolipoprotein B (ApoB)-1.42 ± 2.407-20.43 ± 2.457-23.87 ± 2.457-26.29 ± 2.408
Statistical analysis
  • Placebo vs 2.5 mg Obicetrapib · Mixed Models Analysis · p = <.0001 (p value is calculated) · Least squares (ls) means: -19.00 · 95% CI -25.83 to -12.18mixed model for repeated measures (MMRM) with missing at random assumption
  • Placebo vs 5 mg Obicetrapib · Mixed Models Analysis · p = <.0001 (p value is calculated) · Least squares (ls) means: -22.45 · 95% CI -29.28 to -15.62mixed model for repeated measures (MMRM) with missing at random assumption
  • Placebo vs 10 mg Obicetrapib · Mixed Models Analysis · p = <.0001 (p value is calculated) · Least squares (ls) means: -24.86 · 95% CI -31.62 to -18.10mixed model for repeated measures (MMRM) with missing at random assumption
SecondaryMean Percent Change in Non-high-density Lipoprotein Cholesterol (Non-HDL-C)

Mean percent change from baseline to Day 56 in non-high-density lipoprotein cholesterol (non-HDL-C) (mg/dL) for each obicetrapib group compared with the placebo group

Time frame:
8 weeks
Reported as:
Mean · percent change from baseline
Mean Percent Change in Non-high-density Lipoprotein Cholesterol (Non-HDL-C)
percent change from baselinePlacebo2.5 mg Obicetrapib5 mg Obicetrapib10 mg Obicetrapib
Mean Percent Change in Non-high-density Lipoprotein Cholesterol (Non-HDL-C)-1.80 ± 12.328-25.42 ± 19.280-30.38 ± 13.839-30.25 ± 23.318
Statistical analysis
  • Placebo vs 2.5 mg Obicetrapib · Mixed Models Analysis · p = <.0001 (p value is calculated) · Least squares (ls) means: -23.94 · 95% CI -33.56 to -14.31
  • Placebo vs 5 mg Obicetrapib · Mixed Models Analysis · p = <.0001 (p value is calculated) · Least squares (ls) means: -28.39 · 95% CI -38.01 to -18.76mixed model for repeated measures (MMRM) with missing at random assumption
  • Placebo vs 10 mg Obicetrapib · Mixed Models Analysis · p = <.0001 (p value is calculated) · Least squares (ls) means: -28.55 · 95% CI -38.08 to -19.03mixed model for repeated measures (MMRM) with missing at random assumption
SecondaryMedian Percent Change in Non-high-density Lipoprotein Cholesterol (Non-HDL-C)

Median percent change from baseline to Day 56 in non-high-density lipoprotein cholesterol (non-HDL-C) (mg/dL) for each obicetrapib group compared with the placebo group

Time frame:
8 Weeks
Reported as:
Median · percent change from baseline
Median Percent Change in Non-high-density Lipoprotein Cholesterol (Non-HDL-C)
percent change from baselinePlacebo2.5 mg Obicetrapib5 mg Obicetrapib10 mg Obicetrapib
Median Percent Change in Non-high-density Lipoprotein Cholesterol (Non-HDL-C)-0.37 (-33.3 to 24.2)-23.74 (-62.4 to 15.6)-29.82 (-52.8 to 1.3)-36.96 (-66.3 to 35.8)
Statistical analysis
  • Placebo vs 2.5 mg Obicetrapib · Mixed Models Analysis · p = <.0001 (p value is calculated) · Least squares (ls) means: -23.94 · 95% CI -33.56 to -14.31mixed model for repeated measures (MMRM) with missing at random assumption
  • Placebo vs 5 mg Obicetrapib · Mixed Models Analysis · p = <.0001 (p value is calculated) · Least squares (ls) means: -28.39 · 95% CI -38.01 to -18.76mixed model for repeated measures (MMRM) with missing at random assumption
  • Placebo vs 10 mg Obicetrapib · Mixed Models Analysis · p = <.0001 (p value is calculated) · Least squares (ls) means: -28.55 · 95% CI -38.08 to -19.03mixed model for repeated measures (MMRM) with missing at random assumption
SecondaryLS Mean Percent Change in Non-high-density Lipoprotein Cholesterol (Non-HDL-C)

LS Mean percent change from baseline to Day 56 in non-high-density lipoprotein cholesterol (non-HDL-C) (mg/dL) for each obicetrapib group compared with the placebo group

Time frame:
8 Weeks
Reported as:
Least squares mean · percent change from baseline
LS Mean Percent Change in Non-high-density Lipoprotein Cholesterol (Non-HDL-C)
percent change from baselinePlacebo2.5 mg Obicetrapib5 mg Obicetrapib10 mg Obicetrapib
LS Mean Percent Change in Non-high-density Lipoprotein Cholesterol (Non-HDL-C)-1.72 ± 3.395-25.66 ± 3.463-30.11 ± 3.463-30.28 ± 3.395
Statistical analysis
  • Placebo vs 2.5 mg Obicetrapib · Mixed Models Analysis · p = <.0001 (p value is calculated) · Least squares (ls) means: -23.94 · 95% CI -33.56 to -14.31mixed model for repeated measures (MMRM) with missing at random assumption
  • Placebo vs 5 mg Obicetrapib · Mixed Models Analysis · p = <.0001 (p value is calculated) · Least squares (ls) means: -28.39 · 95% CI -38.01 to -18.76mixed model for repeated measures (MMRM) with missing at random assumption
  • Placebo vs 10 mg Obicetrapib · Mixed Models Analysis · p = <.0001 (p value is calculated) · Least squares (ls) means: -28.55 · 95% CI -38.08 to -19.03mixed model for repeated measures (MMRM) with missing at random assumption
SecondaryMean Percent Change in High-density Lipoprotein Cholesterol (HDL-C)

Mean percent change from baseline to Day 56 in High-density lipoprotein cholesterol (HDL-C) (mg/dL) for each obicetrapib group compared with the placebo group

Time frame:
8 weeks
Reported as:
Mean · percent change from baseline
Mean Percent Change in High-density Lipoprotein Cholesterol (HDL-C)
percent change from baselinePlacebo2.5 mg Obicetrapib5 mg Obicetrapib10 mg Obicetrapib
Mean Percent Change in High-density Lipoprotein Cholesterol (HDL-C)5.57 ± 13.271134.75 ± 56.543153.16 ± 46.879158.75 ± 43.171
Statistical analysis
  • Placebo vs 2.5 mg Obicetrapib · Mixed Models Analysis · p = <.0001 (p value is calculated) · Least squares (ls) means: 133.11 · 95% CI 112.85 to 153.36mixed model for repeated measures (MMRM) with missing at random assumption
  • Placebo vs 5 mg Obicetrapib · Mixed Models Analysis · p = <.0001 (p value is calculated) · Least squares (ls) means: 147.41 · 95% CI 127.17 to 167.64mixed model for repeated measures (MMRM) with missing at random assumption
  • Placebo vs 10 mg Obicetrapib · Mixed Models Analysis · p = <.0001 (p value is calculated) · Least squares (ls) means: 155.98 · 95% CI 135.93 to 176.02mixed model for repeated measures (MMRM) with missing at random assumption
SecondaryMedian Percent Change in High-density Lipoprotein Cholesterol (HDL-C)

Median percent change from baseline to Day 56 in High-density lipoprotein cholesterol (HDL-C) (mg/dL) for each obicetrapib group compared with the placebo group

Time frame:
8 Weeks
Reported as:
Median · percent change from baseline
Median Percent Change in High-density Lipoprotein Cholesterol (HDL-C)
percent change from baselinePlacebo2.5 mg Obicetrapib5 mg Obicetrapib10 mg Obicetrapib
Median Percent Change in High-density Lipoprotein Cholesterol (HDL-C)5.22 (-20.7 to 33.3)114.29 (57.3 to 307.0)144.44 (74.1 to 255.2)158.90 (76.6 to 281.6)
Statistical analysis
  • Placebo vs 2.5 mg Obicetrapib · Mixed Models Analysis · p = <.0001 (p value is calculated) · Least squares (ls) means: 133.11 · 95% CI 112.85 to 153.36mixed model for repeated measures (MMRM) with missing at random assumption
  • Placebo vs 5 mg Obicetrapib · Mixed Models Analysis · p = <.0001 (p value is calculated) · Least squares (ls) means: 147.41 · 95% CI 127.17 to 167.64mixed model for repeated measures (MMRM) with missing at random assumption
  • Placebo vs 10 mg Obicetrapib · Mixed Models Analysis · p = <.0001 (p value is calculated) · Least squares (ls) means: 155.98 · 95% CI 135.93 to 176.02mixed model for repeated measures (MMRM) with missing at random assumption
SecondaryLS Mean Percent Change in High-density Lipoprotein Cholesterol (HDL-C)

LS Mean percent change from baseline to Day 56 in High-density lipoprotein cholesterol (HDL-C) (mg/dL) for each obicetrapib group compared with the placebo group.

Time frame:
8 Weeks
Reported as:
Least squares mean · percent change from baseline
LS Mean Percent Change in High-density Lipoprotein Cholesterol (HDL-C)
percent change from baselinePlacebo2.5 mg Obicetrapib5 mg Obicetrapib10 mg Obicetrapib
LS Mean Percent Change in High-density Lipoprotein Cholesterol (HDL-C)3.90 ± 7.141137.00 ± 7.284151.30 ± 7.282159.87 ± 7.139
Statistical analysis
  • Placebo vs 2.5 mg Obicetrapib · Mixed Models Analysis · p = <.0001 (p value is calculated) · Least squares (ls) means: 133.11 · 95% CI 112.85 to 153.36mixed model for repeated measures (MMRM) with missing at random assumption
  • Placebo vs 5 mg Obicetrapib · Mixed Models Analysis · p = <.0001 (p value is calculated) · Least squares (ls) means: 147.41 · 95% CI 127.17 to 167.64mixed model for repeated measures (MMRM) with missing at random assumption
  • Placebo vs 10 mg Obicetrapib · Mixed Models Analysis · p = <.0001 (p value is calculated) · Least squares (ls) means: 155.98 · 95% CI 135.93 to 176.02mixed model for repeated measures (MMRM) with missing at random assumption

Adverse events

Collected over From first dose of study drug through Week 12. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/26 (0%)0/26 (0%)15/26 (57.7%)
Experimental 2.5 mg Obicetrapib0/25 (0%)0/25 (0%)9/25 (36%)
Experimental 5 mg Obicetrapib0/25 (0%)1/25 (4%)7/25 (28%)
Experimental 10 mg Obicetrapib0/26 (0%)0/26 (0%)15/26 (57.7%)
Most frequent serious events
Most frequent serious events
EventPlaceboExperimental 2.5 mg ObicetrapibExperimental 5 mg ObicetrapibExperimental 10 mg Obicetrapib
Angina pectorisCardiac disorders0/260/251/250/26
Most frequent other events
Showing 10 of 44
Most frequent other events
EventPlaceboExperimental 2.5 mg ObicetrapibExperimental 5 mg ObicetrapibExperimental 10 mg Obicetrapib
NasopharyngitisInfections and infestations3/260/251/252/26
Back painMusculoskeletal and connective tissue disorders3/260/250/252/26
Diabetes mellitusMetabolism and nutrition disorders0/262/250/251/26
HypoglycaemiaMetabolism and nutrition disorders0/262/250/251/26
HyperglycaemiaMetabolism and nutrition disorders2/260/250/250/26
Rhinitis allergicRespiratory, thoracic and mediastinal disorders0/260/250/252/26
COVID-19Infections and infestations1/260/251/251/26
Type 2 diabetes mellitusMetabolism and nutrition disorders0/260/251/250/26
Muscle spasmsMusculoskeletal and connective tissue disorders0/261/250/250/26
MyalgiaMusculoskeletal and connective tissue disorders0/261/250/250/26

Baseline characteristics

Baseline Population is defined as all participants who received at least one dose of study drug and had a baseline value for LDL-C assessment.

Age, Continuous
Age, Continuous(years)Placebo2.5 mg Obicetrapib5 mg Obicetrapib10 mg ObicetrapibTotal
Mean63.3 ± 9.4465.8 ± 8.0967.8 ± 9.4662.5 ± 9.9064.8 ± 9.36
Sex: Female, Male
Sex: Female, Male(Participants)Placebo2.5 mg Obicetrapib5 mg Obicetrapib10 mg ObicetrapibTotal
Female6106729
Male2015191973
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Placebo2.5 mg Obicetrapib5 mg Obicetrapib10 mg ObicetrapibTotal
Hispanic or Latino00000
Not Hispanic or Latino26252526102
Unknown or Not Reported00000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Placebo2.5 mg Obicetrapib5 mg Obicetrapib10 mg ObicetrapibTotal
American Indian or Alaska Native00000
Asian26252526102
Native Hawaiian or Other Pacific Islander00000
Black or African American00000
White00000
More than one race00000
Unknown or Not Reported00000
Baseline Low-Density Lipoprotein Cholesterol (LDL-C) Values
Baseline Low-Density Lipoprotein Cholesterol (LDL-C) Values(milligrams per deciliter (mg/dL))Placebo2.5 mg Obicetrapib5 mg Obicetrapib10 mg ObicetrapibTotal
Mean110.1 ± 37.13102.2 ± 26.58106.4 ± 27.54109.1 ± 32.47106.95 ± 30.93
09

Study locations

10 sites
  • Nippon Kokan Fukuyama Hospital
    Fukuyama, Japan
  • Nakamura Cardiology and Cardiovascular Surgery Clinic
    Itoshima, Japan
  • Kishiwada Tokushu-Kai Hospital
    Osaka, Japan
  • Kyosokai AMC NISHI-UMEDA Clinic
    Osaka, Japan
  • Sakurabashi Watanabe Hospital
    Osaka, Japan
  • Uji Tokushu-Kai Hospital
    Osaka, Japan
  • Sanai Hospital
    Saitama, Japan
  • Shinden Higashi Clinic
    Sendai, Japan
  • Soka-Sugiura Clinic
    Soka, Japan
  • Sugiura Clinic
    Tokyo, Japan
10

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

11

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2022 to primary completion in Mar 2023, 8 months.

Results were first posted in Sep 2024, 1 year 6 months after primary completion.

Of 41 industry-sponsored phase 2 interventional studies under Hypercholesterolemia, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 14. This study's 8 months is below that.

Counting every sponsor, half of 48 studies reached it within 10 months; a quarter within 7 and three quarters within 18.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 13, 2022
First posted
Jun 16, 2022
StartActual
Jun 27, 2022
Primary completionActual
Mar 24, 2023
CompletionActual
Apr 21, 2023
Results first posted
Sep 27, 2024
Last update
Oct 29, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 29, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT05421078
Lead sponsor
NewAmsterdam Pharma
Responsible party
Sponsor
First posted
Jun 16, 2022
Start date
Jun 27, 2022
Primary completion
Mar 24, 2023
Completion
Apr 21, 2023
Results posted
Sep 27, 2024
Last update
Oct 29, 2024

Study contacts

Marc Ditmarsch, MD
study director · NewAmsterdam Pharma

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: TA-8995

Start the discussion